fbpx

Cannabidiol in refractory status epilepticus: A review of clinical experiences

To summarize and evaluate clinical experiences with refractory status epilepticus in which cannabidiol (CBD) was utilized for cessation of seizure activity. A comprehensive literature review was performed on PubMED, MEDLINE, Scopus, and CINAHL between May – June 2022 with the assistance of a medical reference librarian using the following search terms: “Cannabidiol” [MAJR], “Status Epilepticus” [MAJR], “New-Onset Refractory Status Epilepticus”, and “cannabidiol.” Reports that provided dosing regimens and patient outcomes were included.

The post Cannabidiol in refractory status epilepticus: A review of clinical experiences appeared first on Society of Cannabis Clinicians.

Leave a Reply

%d bloggers like this: